Compass Therapeutics Stock Forecast

Stock Price Forecast

According to 15 analysts polled by S&P Global, Compass Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $8.50. The average 1-year stock price forecast is 276.11% higher than the current stock price, while the lowest is $4.00 (+76.99%) and the highest is $24 (+961.95%).

Price Target: $8.50 (+276.11%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$4.00	$8.50	$6.50	$24
Change	+76.99%	+276.11%	+187.61%	+961.95%

Analyst Ratings

The average analyst rating for Compass Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Feb '26	Mar '26	Apr '26	May '26	Jun '26	Jul '26
Strong Buy	13	13	12	11	11	12
Buy	3	3	2	2	2	2
Hold	0	0	1	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	16	16	15	14	14	15

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
John Newman Canaccord Genuity	Canaccord Genuity	Buy Maintains $7	Buy	Maintains	$7	+209.73%	Jul 1, 2026
Biren Amin Piper Sandler	Piper Sandler	Buy Maintains $12 → $4	Buy	Maintains	$12 → $4	+76.99%	Jun 1, 2026
Stephen Willey Stifel Nicolaus	Stifel Nicolaus	Buy Maintains $6	Buy	Maintains	$6	+165.49%	Jun 1, 2026
Joseph Pantginis H.C. Wainwright	H.C. Wainwright	Buy Reiterates $10 → $24	Buy	Reiterates	$10 → $24	+961.95%	Jun 1, 2026
Charles Zhu LifeSci Capital	LifeSci Capital	Buy Maintains $6	Buy	Maintains	$6	+165.49%	May 10, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

-2.06M

Revenue Next Year

25.27M

from -2.06M

EPS This Year

-0.43

from -0.42

EPS Next Year

-0.46

from -0.43

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	-	-	-	850.00K	-	-2.06M
Gross Profit	-	-	-	850.00K	-	-1.75M
Gross Margin	-	-	-	100.00%	-	85.00%
Operating Income	-31.26M	-41.66M	-50.36M	-56.63M	-72.84M	-86.22M
Net Income	-82.18M	-39.23M	-42.49M	-49.38M	-66.49M	-82.44M
EPS	-	-	-	-	-0.42	-0.43
Free Cash Flow	-8.46M	-19.17M	-25.20M	-27.80M	-26.16M	-71.63M
No. Analysts	-	-	-	-	-	14

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	n/a
Avg	-2.1M
Low	-28.8M

Revenue Growth

Revenue Growth	2027	2028
High	-
Avg	-
Low	-

EPS Forecast

EPS	2026	2027	2028
High	-0.33
Avg	-0.43
Low	-0.59

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-